via PsychedelicNewsWire (“PNW”) — Following three impactful
conferences, Arrowhead Sci-Tech Conferences and Events
(“Arrowhead”) is pleased to announce the 4th Annual Psychedelic
Therapeutics and Drug Development Conference (“the
event”), the flagship event for research and therapeutics
development in the psychedelics space, will be held May 23-24,
2024. The event will be hosted in the historic downtown
center at the iconic Revere Hotel Boston Common, 200 Stuart Street,
Boston, MA 02116.
The two-day event attracts the world’s leading researchers and
thought leaders in academia, industry, the non-profit sector, and
government that aim to bridge gaps in the R&D sphere related to
therapeutic psychedelics. The conference has focus on research and
development of psychedelics for various health conditions with
considerable unmet need including inflammatory/autoimmune
disorders, brain injury, pain, PTSD, anxiety, ADHD, headaches,
depression, and opioid use disorder. This distinctive event is
curated to optimize business efficacy and impart invaluable
practical guidance for collaborative partnerships among disparate
disciplines with common objectives.
An elite roster of speakers will share insights and wide-ranging
perspectives on a variety of core themes including Clinical Trial
Design, Intellectual Property, Regulatory Guidance, Psychedelic
Drug Delivery, Commercialization, Legal Issues, Emerging
Preclinical Science, and New Clinical Data among other topics.
Nearly 40 industry thought leaders will engage and interact with
attendees in a variety of formats including in-depth presentations
and lively panel discussions. Featured speakers include Deborah
Mash, Ph.D., Chief Executive Officer and Founder of DemeRx and
Professor Emerita at the University of Miami’s Miller School of
Medicine; Charles Nichols, Ph.D., Professor, LSU Health Sciences
Center; Bernard Lerer, MD, Professor of Psychiatry, Hebrew
University; and Alan Kozikowski, Ph.D., Chief Scientific Officer,
PurMinds Neuropharma.
Peter Hendricks, Ph.D., Professor, Department of Psychiatry,
University of Alabama Birmingham will chair the conference and also
deliver opening remarks on both Day 1 and Day 2.
Panel discussions will explore topics of crucial significance
including “Optimizing Psychedelic Trials: Therapy, Monitoring and
Artificial Intelligence”, “Navigating Legal Challenges in Research:
Best Practices Under the Federal Analogue Act”, “Can Psychedelics
be an Effective Treatment for Pain”, “Psychedelics to Cognitive
Assessments: Bringing Precision Medicine to Mental Health Care”,
“Reimagining the Framework for Psychedelic Research and Access:
Progress and Barriers”, and “Where is the Science of Psychedelics
Taking Us? New Directions and Detours”.
Attendees have the unique opportunity to delve into developments
at the cutting-edge of psychedelic therapeutics while select
researchers present their studies during highly innovative
scientific poster sessions.
The agenda also includes an abundance of networking
opportunities as well as continental breakfast and luncheons on
both days and periodic refreshment breaks.
At the close of Day 1, speakers and attendees are invited to
attend the evening reception where they can mingle with industry
peers in a relaxed atmosphere to form and cement lasting
professional relationships.
To book your tickets, visit
https://psychedelics-conference.com/pricing
To submit a scientific poster for consideration, visit
https://psychedelics-conference.com/scientific-poster-session
For more information on the event, click
https://psychedelics-conference.com/
About Arrowhead Sci-Tech Conferences
& Events
Arrowhead SciTech Conferences & Events is
more than a life sciences event company. Our focus is on bringing
the developments and discoveries in life sciences research together
to help further progress.
We utilize our years of experience to provide
attendees with thoughtfully curated speakers for life sciences
conferences that highlight new research, industry trends, case
studies, emerging discoveries and the future focus of the biotech
and pharmaceutical industries. Our conferences cover: clinical
development and cutting-edge research, regulatory issues and market
dynamics, therapeutics, drug discovery and positioning, and
emerging technologies for both clinicians and pharmaceutical
professionals.
At Arrowhead, we strive to provide a platform of
excellence for attendees. To execute this, we consult with
dedicated advisory boards, comprised of industry insiders to ensure
that the topics and speakers we feature are highly relevant and
valuable. Our conference speakers come from clinical, business and
academic environments to provide well-rounded insights and
perspectives on developments within the Life Sciences industry.
Arrowhead's conferences offer more than
presentations; we offer an experience that encompasses learning,
networking and professional growth. We focus on bringing life
sciences industry professionals together to help move research
forward.
Arrowhead sponsorship and exhibitor levels are
designed to give your organization the highest level of exposure
and opportunity to market products and branding in an environment
that is targeted toward facilitating professional networking. We
can also build tailor-made packages that will meet your
organization's marketing budget and goals. Arrowhead sponsorships
are proven to help grow businesses through direct and targeted
exposure to industry leaders and decision makers. To gain critical
industry exposure via our sponsorship and exhibiting opportunities,
please contact us.
About IBNIBN is a cutting-edge corporate
communications and content distribution company consisting of over
60+ investor facing brands introduced to the investment public over
the last 18+ years while amassing a collective audience of millions
of social media followers. These distinctive investor brands aim to
fulfil the unique needs of a growing base of client-partners. IBN
will continue to expand our branded network of highly influential
properties, leveraging the knowledge and energy of specialized
teams of experts to serve our increasingly diversified list of
clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides:
(1) access to a network of wire solutions
via InvestorWire to reach all target markets, industries
and demographics in the most effective manner possible; (2) article
and editorial syndication to 5,000+ news outlets;
(3) Press Release Enhancement to ensure maximum impact;
(4) full-scale distribution to a growing social
media audience; (5) a full array of corporate
communications solutions; and (6) total news coverage
solutions.
For more information, please
visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the
InvestorBrandNetwork website applicable to all content provided by
IBN, wherever published or
re-published: http://IBN.fm/Disclaimer
Corporate Communications
IBNLos Angeles,
Californiawww.InvestorBrandNetwork.com310.299.1717
OfficeEditor@InvestorBrandNetwork.com